Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from Elekta AB ( ($SE:EKTA.B) ).
Elekta’s Investor Update in Stockholm showcased its innovative portfolio and strategic growth plans, including restoring gross margin and achieving a 14% EBIT margin. The company highlighted its proactive order review, resulting in a SEK 4.9 billion cancellation, and discussed the positive market reception of its latest products, emphasizing the importance of adaptive radiation therapy in improving clinical outcomes.
The most recent analyst rating on ($SE:EKTA.B) stock is a Sell with a SEK71.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.
More about Elekta AB
Elekta is a leader in precision radiation therapy, dedicated to providing the best cancer care through sustainable, outcome-driven, and cost-efficient solutions. With a global team of 4,500 employees, Elekta is headquartered in Stockholm, Sweden, and operates in over 40 countries, focusing on advancing cancer care technology.
Average Trading Volume: 1,336,135
Current Market Cap: SEK19.09B
For a thorough assessment of EKTA.B stock, go to TipRanks’ Stock Analysis page.